We are analyzing https://link.springer.com/article/10.1007/s10637-010-9478-3.

Title:
A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer | Investigational New Drugs
Description:
Purpose: We investigated a combination therapy with weekly paclitaxel and all trans-retinoic acid (ATRA) for tolerability, response to treatment, time to progression and survival in previously treated patients with metastatic or recurrent breast cancer. Our rationale was based on preclinical studies demonstrating potentiation of the cytotoxic effects of taxanes and induction of differentiation by ATRA. Patients and methods: Seventeen patients with previously treated metastatic or recurrent breast cancer were enrolled to a regimen of all-trans retinoic acid (Vesanoid, tretinoin, Hoffman-La Roche, Inc.) 45 mg/m2 PO daily for 4 days starting 2 days before a 1 h treatment with paclitaxel (Taxol, Bristol-Myers Squibb, Plainsboro, NJ) 80 mg/m2 IV administered weekly for 3 weeks, repeated in 28 day cycles until disease progression or until no longer tolerated. Patients were evaluated for toxicity, response, time to progression and survival. Patients were primarily African American and Latino, representative of the population served by our Cancer Center. Results: The regimen was relatively well tolerated. There were nine grade 3 and one grade 4 toxic events. We administered 162 treatment cycles with a mean of 7.5 per patient (range 1–22, median 5). Three patients had a partial response (17.6%) and ten patients had stable disease (58.8%), with an overall clinical benefit of 76.4%. Median time to progression was 6.0 months (range 1–21, mean 7.7 months). Fourteen evaluable patients had a median survival of 16 months (range 1–68 months, mean 25.2 months). Conclusions: The data suggest this is a well tolerated regimen with modest response rates but with time to progression and survival rates similar to those reported for paclitaxel alone and relatively high rates of stable disease in this sample of patients.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Telecommunications

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

cancer, breast, google, scholar, article, patients, pubmed, cas, metastatic, phase, acid, trial, paclitaxel, retinoic, clin, alltrans, weekly, oncol, privacy, cookies, content, research, treatment, progression, survival, center, months, cells, usa, data, information, publish, search, taxol, recurrent, robert, response, time, results, access, study, winer, res, tamoxifen, kinase, log, journal, drugs, pilot, vesanoid,

Topics {✒️}

asp-glu-val-asp-directed chemotherapy-induced cell death jun n-terminal kinase month download article/chapter tracie saunders & robert wieder 45 mg/m2 po daily cell-specific additive effects study drug supplied jersey medical school trans retinoic acid trans-retinoic acid trans-retinoic acid breast cancer cells differentiation-inducing therapy metastatic breast cancer combination therapy 9-cis retinoic acid phase ii trial chemoresistant breast cancer full article pdf privacy choices/manage cookies related subjects somerset medical center advanced breast cancer steeplechase cancer center cancer center h1216 paclitaxel-induced apoptosis additional information support recurrent breast cancer breast cancer patients anglo-celtic iv previously treated metastatic european economic area hoffman-la roche 4 days starting 2 days bristol-myers squibb primarily african american infusion hypersensitivity reaction withholding dexamethasone premedication subsequent bcl-2 phosphorylation alpha-interferon 2a 1007/s10637-010-9478-3 keywords conditions privacy policy breast cancer article investigational higher-dose paclitaxel article bryan accepting optional cookies kaiser-kupfer mi cancer center

Schema {🗺️}

WebPage:
      mainEntity:
         headline:A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer
         description:Purpose: We investigated a combination therapy with weekly paclitaxel and all trans-retinoic acid (ATRA) for tolerability, response to treatment, time to progression and survival in previously treated patients with metastatic or recurrent breast cancer. Our rationale was based on preclinical studies demonstrating potentiation of the cytotoxic effects of taxanes and induction of differentiation by ATRA. Patients and methods: Seventeen patients with previously treated metastatic or recurrent breast cancer were enrolled to a regimen of all-trans retinoic acid (Vesanoid, tretinoin, Hoffman-La Roche, Inc.) 45 mg/m2 PO daily for 4 days starting 2 days before a 1 h treatment with paclitaxel (Taxol, Bristol-Myers Squibb, Plainsboro, NJ) 80 mg/m2 IV administered weekly for 3 weeks, repeated in 28 day cycles until disease progression or until no longer tolerated. Patients were evaluated for toxicity, response, time to progression and survival. Patients were primarily African American and Latino, representative of the population served by our Cancer Center. Results: The regimen was relatively well tolerated. There were nine grade 3 and one grade 4 toxic events. We administered 162 treatment cycles with a mean of 7.5 per patient (range 1–22, median 5). Three patients had a partial response (17.6%) and ten patients had stable disease (58.8%), with an overall clinical benefit of 76.4%. Median time to progression was 6.0 months (range 1–21, mean 7.7 months). Fourteen evaluable patients had a median survival of 16 months (range 1–68 months, mean 25.2 months). Conclusions: The data suggest this is a well tolerated regimen with modest response rates but with time to progression and survival rates similar to those reported for paclitaxel alone and relatively high rates of stable disease in this sample of patients.
         datePublished:2010-07-02T00:00:00Z
         dateModified:2010-07-02T00:00:00Z
         pageStart:1482
         pageEnd:1487
         sameAs:https://doi.org/10.1007/s10637-010-9478-3
         keywords:
            All trans retinoic acid
            Taxol
            Metastatic breast cancer
            Potentiation
            Oncology
            Pharmacology/Toxicology
         image:
         isPartOf:
            name:Investigational New Drugs
            issn:
               1573-0646
               0167-6997
            volumeNumber:29
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Margarette Bryan
               affiliation:
                     name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
                     address:
                        name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:E. Dianne Pulte
               affiliation:
                     name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
                     address:
                        name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kathleen C. Toomey
               affiliation:
                     name:The Steeplechase Cancer Center at Somerset Medical Center
                     address:
                        name:The Steeplechase Cancer Center at Somerset Medical Center, Somerville, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lillian Pliner
               affiliation:
                     name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
                     address:
                        name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Anna C. Pavlick
               affiliation:
                     name:New York University Cancer Institute
                     address:
                        name:New York University Cancer Institute, New York, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Tracie Saunders
               affiliation:
                     name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
                     address:
                        name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Robert Wieder
               affiliation:
                     name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
                     address:
                        name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
                        type:PostalAddress
                     type:Organization
                     name:UMDNJ-New Jersey Medical School
                     address:
                        name:UMDNJ-New Jersey Medical School, Newark, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer
      description:Purpose: We investigated a combination therapy with weekly paclitaxel and all trans-retinoic acid (ATRA) for tolerability, response to treatment, time to progression and survival in previously treated patients with metastatic or recurrent breast cancer. Our rationale was based on preclinical studies demonstrating potentiation of the cytotoxic effects of taxanes and induction of differentiation by ATRA. Patients and methods: Seventeen patients with previously treated metastatic or recurrent breast cancer were enrolled to a regimen of all-trans retinoic acid (Vesanoid, tretinoin, Hoffman-La Roche, Inc.) 45 mg/m2 PO daily for 4 days starting 2 days before a 1 h treatment with paclitaxel (Taxol, Bristol-Myers Squibb, Plainsboro, NJ) 80 mg/m2 IV administered weekly for 3 weeks, repeated in 28 day cycles until disease progression or until no longer tolerated. Patients were evaluated for toxicity, response, time to progression and survival. Patients were primarily African American and Latino, representative of the population served by our Cancer Center. Results: The regimen was relatively well tolerated. There were nine grade 3 and one grade 4 toxic events. We administered 162 treatment cycles with a mean of 7.5 per patient (range 1–22, median 5). Three patients had a partial response (17.6%) and ten patients had stable disease (58.8%), with an overall clinical benefit of 76.4%. Median time to progression was 6.0 months (range 1–21, mean 7.7 months). Fourteen evaluable patients had a median survival of 16 months (range 1–68 months, mean 25.2 months). Conclusions: The data suggest this is a well tolerated regimen with modest response rates but with time to progression and survival rates similar to those reported for paclitaxel alone and relatively high rates of stable disease in this sample of patients.
      datePublished:2010-07-02T00:00:00Z
      dateModified:2010-07-02T00:00:00Z
      pageStart:1482
      pageEnd:1487
      sameAs:https://doi.org/10.1007/s10637-010-9478-3
      keywords:
         All trans retinoic acid
         Taxol
         Metastatic breast cancer
         Potentiation
         Oncology
         Pharmacology/Toxicology
      image:
      isPartOf:
         name:Investigational New Drugs
         issn:
            1573-0646
            0167-6997
         volumeNumber:29
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Margarette Bryan
            affiliation:
                  name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
                  address:
                     name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:E. Dianne Pulte
            affiliation:
                  name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
                  address:
                     name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kathleen C. Toomey
            affiliation:
                  name:The Steeplechase Cancer Center at Somerset Medical Center
                  address:
                     name:The Steeplechase Cancer Center at Somerset Medical Center, Somerville, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lillian Pliner
            affiliation:
                  name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
                  address:
                     name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Anna C. Pavlick
            affiliation:
                  name:New York University Cancer Institute
                  address:
                     name:New York University Cancer Institute, New York, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Tracie Saunders
            affiliation:
                  name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
                  address:
                     name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Robert Wieder
            affiliation:
                  name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
                  address:
                     name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
                     type:PostalAddress
                  type:Organization
                  name:UMDNJ-New Jersey Medical School
                  address:
                     name:UMDNJ-New Jersey Medical School, Newark, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Investigational New Drugs
      issn:
         1573-0646
         0167-6997
      volumeNumber:29
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
      address:
         name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
         type:PostalAddress
      name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
      address:
         name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
         type:PostalAddress
      name:The Steeplechase Cancer Center at Somerset Medical Center
      address:
         name:The Steeplechase Cancer Center at Somerset Medical Center, Somerville, USA
         type:PostalAddress
      name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
      address:
         name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
         type:PostalAddress
      name:New York University Cancer Institute
      address:
         name:New York University Cancer Institute, New York, USA
         type:PostalAddress
      name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
      address:
         name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
         type:PostalAddress
      name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
      address:
         name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
         type:PostalAddress
      name:UMDNJ-New Jersey Medical School
      address:
         name:UMDNJ-New Jersey Medical School, Newark, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Margarette Bryan
      affiliation:
            name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
            address:
               name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
               type:PostalAddress
            type:Organization
      name:E. Dianne Pulte
      affiliation:
            name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
            address:
               name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
               type:PostalAddress
            type:Organization
      name:Kathleen C. Toomey
      affiliation:
            name:The Steeplechase Cancer Center at Somerset Medical Center
            address:
               name:The Steeplechase Cancer Center at Somerset Medical Center, Somerville, USA
               type:PostalAddress
            type:Organization
      name:Lillian Pliner
      affiliation:
            name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
            address:
               name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
               type:PostalAddress
            type:Organization
      name:Anna C. Pavlick
      affiliation:
            name:New York University Cancer Institute
            address:
               name:New York University Cancer Institute, New York, USA
               type:PostalAddress
            type:Organization
      name:Tracie Saunders
      affiliation:
            name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
            address:
               name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
               type:PostalAddress
            type:Organization
      name:Robert Wieder
      affiliation:
            name:UMDNJ-New Jersey Medical School/University Hospital Cancer Center
            address:
               name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
               type:PostalAddress
            type:Organization
            name:UMDNJ-New Jersey Medical School
            address:
               name:UMDNJ-New Jersey Medical School, Newark, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
      name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
      name:The Steeplechase Cancer Center at Somerset Medical Center, Somerville, USA
      name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
      name:New York University Cancer Institute, New York, USA
      name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
      name:Department of Medicine, UMDNJ-New Jersey Medical School/University Hospital Cancer Center, Newark, USA
      name:UMDNJ-New Jersey Medical School, Newark, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(84)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.15s.

LINK . SPRINGER . COM {}